

Ian Chau

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7317812/ian-chau-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

441
papers

24,401
citations

58
h-index

151
g-index

516
ext. papers

29,788
ext. citations

5.6
avg, IF

6.51
L-index

#	Paper	IF	Citations
441	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials.. <i>Expert Opinion on Investigational Drugs</i> , 2022 ,	5.9	3
440	Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-9	4.1	0
439	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS224-TPS224	2.2	0
438	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.. <i>New England Journal of Medicine</i> , 2022 , 386, 449-462	59.2	30
437	Approach to Immunotherapy in Oesophageal Cancer 2022 , 1		
436	Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.. <i>Current Oncology</i> , 2022 , 29, 2174-2184	2.8	
435	HER2 targeted therapy in colorectal cancer: New horizons.. <i>Cancer Treatment Reviews</i> , 2022 , 105, 102363	4.4	2
434	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022 , 82, PR012-PR012	10.1	
433	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022 , 82, A002-A002	10.1	
432	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-19	5.9	0
431	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-13	3.5	
430	Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. <i>Leukemia and Lymphoma</i> , 2021 , 1-11	1.9	
429	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021 , 12, 6738	17.4	1
428	Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	
427	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	17
426	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	24
425	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3978-3992	2.2	12

424	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101440	2.2	55
423	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021 , 70, 1632-1641	19.2	11
422	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. <i>Gut</i> , 2021 , 70, 1904-1913	19.2	9
421	Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. <i>American Journal of Roentgenology</i> , 2021 , 216, 669-676	5.4	6
420	F-choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma. <i>British Journal of Haematology</i> , 2021 , 193, 1026	4.5	3
419	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3926-3935	12.9	19
418	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1429-1441	4	0
417	Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer. <i>Lancet Oncology</i> , 2021 , 22, 739-741	21.7	0
416	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS3620-TPS3620	2.2	3
415	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. <i>Nature Ecology and Evolution</i> , 2021 , 5, 1024-1032	12.3	2
414	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, LBA4001-LBA4001	2.2	24
413	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021 , 27, 1362-1366	50.5	26
412	Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4015-4015	2.2	2
411	Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16074-e16074	2.2	0
410	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021 , 7, 895-902	13.4	43
409	Are treatment response assessment maps (TRAMs) and F-choline positron emission tomography the future of central nervous system lymphoma imaging?. <i>British Journal of Haematology</i> , 2021 , 195, e116-e119	4.5	1
408	Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. <i>Clinical Radiology</i> , 2021 , 76, 789-800	2.9	2
407	The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. <i>Supportive Care in Cancer</i> , 2021 , 29, 1443-1453	3.9	5

406	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 289-298	8.9	12
405	A very rare complication of subdural haematoma: fibrin-associated diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 192, 947	4.5	1
404	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. <i>Advances in Therapy</i> , 2021 , 38, 707-720	4.1	1
403	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. <i>Pharmacogenomics</i> , 2021 , 22, 703-726	2.6	0
402	Targeting the Stroma in the Management of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 691185	5.3	2
401	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1159-1167	4.2	2
400	A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. <i>Blood Advances</i> , 2021 , 5, 4073-4082	7.8	0
399	Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021 , 11, 3549-3561	3.6	1
398	LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. <i>Annals of Oncology</i> , 2021 , 32, S1332	10.3	6
397	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2021 , 1	7.6	8
396	443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers □ phase IIA dose finding. <i>Annals of Oncology</i> , 2021 , 32, S555-S556	10.3	2
395	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 933-946	18.8	6
394	386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2021 , 32, S532	10.3	2
393	Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 102-102	2.2	5
392	Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 201-201	2.2	3
391	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
390	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 1-13	1.9	0
389	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases.. <i>Cancer Imaging</i> , 2021 , 21, 67	5.6	0

388	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMJ Open</i> , 2020 , 10, e034527	3	6
387	Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. <i>BMC Gastroenterology</i> , 2020 , 20, 133	3	1
386	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2020 , 21, 431	2.8	
385	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. <i>European Journal of Cancer</i> , 2020 , 135, 103-112	7.5	1
384	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 251-270	3.5	3
383	Focal splenic lesions in indolent B-NHL: association with high grade transformation and safe percutaneous biopsy. <i>British Journal of Haematology</i> , 2020 , 189, e157-e160	4.5	1
382	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 305-324	3.5	
381	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. <i>Cancers</i> , 2020 , 12,	6.6	9
380	O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , 2020 , 31, 236	10.3	4
379	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020 , 5, 299-311	1.6	1
378	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020 , 10, 657-664	6.4	46
377	LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy. <i>British Journal of Haematology</i> , 2020 , 189, e248-e251	4.5	3
376	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3546-3556	12.9	4
375	The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL. <i>Blood</i> , 2020 , 136, 31-32	2.2	
374	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3089-3089	2.2	1
373	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1 β positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4503-4503	2.2	19
372	TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancerA randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC). <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4120-TPS4120	2.2	4
371	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 430-430	2.2	8

370	Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 282-282 ^{2,2}	2.2	1
369	Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with anti-epidermal growth factor receptor (EGFR) therapy in OZONE.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 212-212	2.2	
368	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 712-712	2.2	0
367	SOLar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS471-TPS471	2.2	
366	A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS459-TPS459	2.2	
365	Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 304-304	2.2	
364	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16537-e16537	2.2	
363	MRI-Diagnosed Tumour Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer. <i>Annals of Surgery</i> , 2020 ,	7.8	26
362	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 183-192	12.9	33
361	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020 , 99, 105-112	3	3
360	Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. <i>Journal of Comparative Effectiveness Research</i> , 2020 , 9, 103-114	2.1	1
359	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020 , 10, 1634	5.3	1
358	Early interval and serial positron emission tomography-computed tomography (PET-CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma. <i>British Journal of Haematology</i> , 2020 , 190, e357-e362	4.5	
357	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). <i>European Journal of Cancer</i> , 2020 , 137, 45-56	7.5	16
356	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. <i>European Radiology</i> , 2020 , 30, 6702-6708	8	6
355	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020 , 12,	6.6	8
354	Molecular target: pan-AKT in gastric cancer. <i>ESMO Open</i> , 2020 , 5, e000728	6	11
353	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020 , 5,	6	7

352	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. <i>ESMO Open</i> , 2020 , 5,	6	9
351	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , 2020 , 146, 94-102	7.5	15
350	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 32-38.e3	3.8	10
349	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020 , 23, 133-141	7.6	10
348	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020 , 5,	6	22
347	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. <i>Cancer Treatment Reviews</i> , 2020 , 86, 101998	14.4	17
346	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. <i>European Journal of Cancer</i> , 2019 , 121, 40-47	7.5	17
345	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 420-435	21.7	110
344	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). <i>Clinical Colorectal Cancer</i> , 2019 , 18, 183-191.e3	3.8	11
343	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. <i>Cancers</i> , 2019 , 11,	6.6	9
342	Gastric Cancer - From Aetiology to Management: Differences Between the East and the West. <i>Clinical Oncology</i> , 2019 , 31, 570-577	2.8	13
341	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 782-794	9.7	113
340	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids 2019 , 7, 101		41
339	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 3830-3838	12.9	23
338	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. <i>Current Problems in Cancer</i> , 2019 , 43, 487-494	2.3	5
337	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019 , 9, 618	5.3	6
336	EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R-GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES. <i>Hematological Oncology</i> , 2019 , 37, 425-426	1.3	1
335	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15

334	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 280-291.e5	3.8	11
333	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019 , 36, 35-50.e9	24.3	94
332	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , 2019 , 20, 1109-1123	21.7	113
331	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. <i>Cancers</i> , 2019 , 11,	6.6	12
330	Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. <i>European Journal of Cancer</i> , 2019 , 122, 12-21	7.5	1
329	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 153-163	7	31
328	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) + ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) 2019 ,		7
327	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4022-4022	2.2	2
326	POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomized study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3615-TPS3615	2.2	9
325	Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 128-128	2.2	1
324	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 548-548	2.2	2
323	Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 102-102 ²⁻²		
322	CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 535-535	2.2	
321	A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial. <i>Blood</i> , 2019 , 134, 2879-2879		
320	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment 2019 , 7, 309		46
319	MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF). <i>Journal of Thoracic Oncology</i> , 2019 , 14, S307	8.9	3
318	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019 , 73, 31-40	14.4	9
317	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. <i>European Journal of Cancer</i> , 2019 , 107, 115-123	7.5	20

316	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. <i>European Journal of Cancer</i> , 2019 , 108, 17-24	7.5	17
315	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 237-244	8.9	163
314	Ramucirumab and its use in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2019 , 15, 979-988	9.8	5
313	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 64-71.e1	3.8	5
312	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018 , 359, 920-926	33.3	712
311	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology, The</i> , 2018 , 19, e151-e160	21.7	31
310	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology, the</i> , 2018 , 5, e190-e200	14.6	33
309	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018 , 23, 822-839	5.7	13
308	Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 327-338	3.5	3
307	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. <i>Annals of Oncology</i> , 2018 , 29, 230-236	10.3	16
306	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. <i>Scientific Reports</i> , 2018 , 8, 1445	4.9	43
305	Chemotherapy for Advanced Pancreatic Cancer 2018 , 875-921		
304	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e69-e76	3.8	25
303	The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. <i>British Journal of Haematology</i> , 2018 , 180, 52-59	4.5	5
302	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 814-824	4	14
301	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. <i>Gut</i> , 2018 , 67, 1780-1792	19.2	15
300	Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. <i>BMC Hematology</i> , 2018 , 18, 19	2.5	3
299	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018 , 392, 123-133	40	624

298	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018 , 119, 19-26	8.7	19
297	Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response. <i>Colorectal Disease</i> , 2018 , 20 Suppl 1, 76-81	2.1	1
296	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018 , 23, 1407-e136	5.7	91
295	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018 , 132, 2892-2892	2.2	3
294	Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3059-3059	2.2	3
293	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16207-e16207	2.2	1
292	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4139-TPS4139	2.2	3
291	Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 101-101	2.2	16
290	Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 401-401	2.2	2
289	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5-5	2.2	18
288	Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 51-51	2.2	1
287	Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 658-658	2.2	7
286	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 90-90	2.2	1
285	CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS193-TPS193	2.2	11
284	CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS193-TPS193	2.2	11
283	MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS530-TPS530	2.2	6
282	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018 , 9, 36654-36665	3.3	9
281	Complications and seeding risk after percutaneous liver biopsy in an oncological setting.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 246-246	2.2	1

280	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4044-4044	2.2	1
279	What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16023-e16023	2.2	
278	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15127-e15127	2.2	
277	Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience. <i>Blood</i> , 2018 , 132, 4240-4240	2.2	
276	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , 2018 , 4, 384-388	13.4	191
275	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1586-1595	1.9	7
274	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. <i>Gut</i> , 2018 , 67, 1484-1492	19.2	45
273	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3477-3484	2.2	139
272	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1714-1768	2.2	1740
271	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2836-2844	2.2	296
270	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 280-291	7.1	4
269	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	14
268	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2018 , 10, 159-171	3.4	8
267	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv238-iv255	10.3	355
266	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). <i>Heliyon</i> , 2018 , 4, e00804	3.6	16
265	Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. <i>Anticancer Research</i> , 2018 , 38, 5943-5949	2.3	0
264	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018 , 14, 138-151	1	
263	Neoadjuvant rectal score: run with the hare and hunt with the hounds. <i>Annals of Oncology</i> , 2018 , 29, 2261-2262	10.3	7

262	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018 , 64, 1626-1635	5.5	31
261	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018 , 8, 1270-1285	24.4	130
260	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 280-284	3.8	22
259	Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 223-230	3.8	19
258	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. <i>Oncologist</i> , 2017 , 22, 402-408	5.7	23
257	Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1336.e9-1336.e12	3.8	3
256	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017 , 22, 728-736	5.7	10
255	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. <i>European Journal of Cancer</i> , 2017 , 81, 17-25	7.5	45
254	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017 , 23, 6002-6011	12.9	21
253	Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 529-544	3.1	5
252	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1805-1813	1.9	12
251	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. <i>Annals of Oncology</i> , 2017 , 28, 2932-2942	10.3	63
250	Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?. <i>Lancet, The</i> , 2017 , 390, 2418-2419	4.0	9
249	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017 , 17, 132-144	3.2	36
248	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2279-2287	2.2	74
247	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 951-964	3.5	1
246	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 1478-1485	8.7	64
245	Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2017 , 59, 132-137	14.4	3

244	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017 , 18, 1159-1171	21.7	193
243	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. <i>JAMA Oncology</i> , 2017 , 3, 235-243	13.4	59
242	Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e181-e189	3.8	5
241	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2004-2004	2.2	1
240	Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4014-4014	2.2	44
239	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4046-4046	2.2	11
238	Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4047-4047	2.2	1
237	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7537-7537	2.2	2
236	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9074-9074	2.2	9
235	CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4131-TPS4131	2.2	3
234	CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4132-TPS4132	2.2	4
233	A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4133-TPS4133	2.2	1
232	Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7579-TPS7579 ²	2.2	2
231	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 102-102	2.2	17
230	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3-3	2.2	4
229	CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS212-TPS212	2.2	12
228	Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS213-TPS213	2.2	13
227	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. <i>Oncotarget</i> , 2017 , 8, 64999-65008	3.3	11

226	Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. <i>Current Drug Targets</i> , 2017 , 18, 56-71	3	23
225	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2017 , 9, 333-340	3.4	2
224	Chemotherapy for Advanced Pancreatic Cancer 2017 , 1-48		
223	iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS221-TPS221	2.2	1
222	Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 613-613	2.2	
221	Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 709-709	2.2	1
220	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016 , 37, 852-7	4.6	13
219	Immunotherapy for oesophagogastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1197-207	5.4	6
218	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. <i>Oncologist</i> , 2016 , 21, 1502-1508	5.7	14
217	Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP). <i>Annals of Oncology</i> , 2016 , 27, vi182	10.3	4
216	Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial. <i>Annals of Oncology</i> , 2016 , 27, vi220 ^{10.3}		3
215	Novel STAT 3 inhibitors for treating gastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1023-31	5.9	39
214	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 883-895	21.7	783
213	Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. <i>Trials</i> , 2016 , 17, 17	2.8	99
212	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2016 , 16, 112	4.8	10
211	Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e53-9	3.8	21
210	Management of resectable colorectal lung metastases. <i>Clinical and Experimental Metastasis</i> , 2016 , 33, 285-96	4.7	26
209	Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. <i>Drugs</i> , 2016 , 76, 13-26	12.1	7

208	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. <i>Expert Review of Hematology</i> , 2016 , 9, 123-35	2.8	2
207	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. <i>Gastric Cancer</i> , 2016 , 19, 1114-1124	7.6	8
206	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016 , 128, 480-480	2.2	3
205	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016 , 128, 624-624	2.2	7
204	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3056-3056	2.2	16
203	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4010-4010	2.2	41
202	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 154-154	2.2	12
201	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6-6	2.2	28
200	Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 644-644	2.2	1
199	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS178-TPS178	2.2	2
198	PLATFORM: Planning treatment of oesophago-gastric (OG) cancerA randomised maintenance therapy trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS187-TPS187	2.2	3
197	A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 580-580	2.2	
196	The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS10143-TPS10143	2.2	
195	Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases: Implications for targeted treatment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15027-e15027 ^{2.2}		
194	Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. <i>Translational Gastroenterology and Hepatology</i> , 2016 , 1, 46	5.2	6
193	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. <i>Oncotarget</i> , 2016 , 7, 12672-81	3.3	32
192	Chemotherapy for Advanced Pancreatic Cancer 2016 , 1-48		
191	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1557-65 ^{10.3}		47

190	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016 , 6, 838-851	24.4	176
189	Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. <i>Seminars in Radiation Oncology</i> , 2016 , 26, 176-85	5.5	5
188	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 801-810	21.7	494
187	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 104-125	5.4	5
186	Colorectal cancer trial endpoints: time for dynamic thinking?. <i>Lancet Oncology, The</i> , 2016 , 17, 1345-1347	21.7	
185	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , 2016 , 115, 974-982	8.7	44
184	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 303-12	4	13
183	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 859-70	21.7	542
182	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , 2015 , 26, 1936-1941	10.3	18
181	Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2015 , 26, 804-811	10.3	67
180	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. <i>BMC Cancer</i> , 2015 , 15, 15	4.8	27
179	PD-1 and PD-L1 blockade in gastrointestinal malignancies. <i>Cancer Treatment Reviews</i> , 2015 , 41, 893-903	14.4	44
178	Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2015 , 8, 373-83	4.7	15
177	Does surgery have a role in managing incurable gastric cancer?. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 676-82	19.4	75
176	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2015 , 373, 726-36	59.2	1172
175	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2015 , 94, 219-26	3.8	10
174	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. <i>BMC Cancer</i> , 2015 , 15, 764	4.8	24
173	The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e259-64	1.7	13

172	Pancreatic neuroendocrine tumors: a review. <i>Future Oncology</i> , 2015 , 11, 853-64	3.6	27
171	The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. <i>European Journal of Cancer</i> , 2015 , 51, 2732-9	7.5	5
170	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 115-22.e1-2	3.8	36
169	The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: an exploratory study. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 484-92	3.6	16
168	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. <i>Annals of Oncology</i> , 2015 , 26, 702-708	10.3	190
167	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015 , 126, 4263-4263	2.2	9
166	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2508-2508	2.2	28
165	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4029-4029	2.2	3
164	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4077-4077	2.2	1
163	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS1131-TPS1131	2.2	4
162	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α -fetoprotein (AFP) from the randomized phase III REACH study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 232-232	2.2	12
161	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 581-581	2.2	1
160	Toxicity and efficacy of salvage paclitaxel chemotherapy in Royal Marsden (RM) oesophagogastric adenocarcinoma (OGA) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 188-188	2.2	
159	A prospective patient (pt) survey on clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 707-707	2.2	
158	Trends in resected oesophageal and gastric adenocarcinoma (OGA) outcomes: Royal Marsden (RM) experience 2001-2010.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 169-169	2.2	
157	Formulating a surveillance strategy following surgery for oesophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 153-153	2.2	
156	FORMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS227-TPS227	2.2	
155	Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4028-4028	2.2	

154	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4108-4108	2.2	
153	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. <i>Blood</i> , 2015 , 126, 1499-1499	2.2	
152	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. <i>Annals of Hematology</i> , 2014 , 93, 827-34	3	8
151	What studies are appropriate and necessary for staging gastric adenocarcinoma? Results of an international RAND/UCLA expert panel. <i>Gastric Cancer</i> , 2014 , 17, 377-82	7.6	13
150	EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. <i>Annals of Oncology</i> , 2014 , 25, 858-863	10.3	64
149	RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. <i>European Journal of Cancer</i> , 2014 , 50, 1430-6	7.5	26
148	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2014 , 383, 31-39	40	1475
147	FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 232-8	3.8	55
146	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014 , 50, 3136-44	7.5	15
145	Ramucirumab: successfully targeting angiogenesis in gastric cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5875-81	12.9	52
144	A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. <i>BMC Cancer</i> , 2014 , 14, 605	4.8	30
143	Guidance on the management of diarrhoea during cancer chemotherapy. <i>Lancet Oncology, The</i> , 2014 , 15, e447-60	21.7	128
142	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	44
141	Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. <i>British Journal of Cancer</i> , 2014 , 110, 19-25	8.7	101
140	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2014 , 15, 78-86	21.7	413
139	A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 94-9	3.8	22
138	Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2014 , 96, 543-6	1.4	18
137	Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. <i>Immunotherapy</i> , 2014 , 6, 1177-86	3.6	5

136	Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. <i>JAMA Surgery</i> , 2014 , 149, 18-25	5.4	29
135	Investigational therapies targeting the ErbB family in oesophagogastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1349-63	5.9	3
134	Fc β IIa and Fc β IIIa polymorphisms and cetuximab benefit in the microscopic disease. <i>Clinical Cancer Research</i> , 2014 , 20, 4511-9	12.9	7
133	Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. <i>Annals of Surgery</i> , 2014 , 259, 102-8	7.8	42
132	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. <i>European Journal of Cancer</i> , 2014 , 50, 1422-9	7.5	25
131	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. <i>Blood</i> , 2014 , 124, 1719-1719	2.2	1
130	VE-BASKET, a first-in-kind, phase II, histology-independent Basket study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2533-2533	2.2	8
129	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2513-2513	2.2	17
128	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3575-3575	2.2	5
127	Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4016-4016	2.2	12
126	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2513-2513	2.2	3
125	Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4067-4067	2.2	2
124	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3114-TPS3114	2.2	9
123	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3115-TPS3115	2.2	2
122	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 489-489	2.2	2
121	Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12391-406	5.6	43
120	Exclusion of patients with prior cancers from clinical trials: Is this justified?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6544-6544	2.2	
119	FC β IIa and FC β IIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3573-3573	2.2	

118	LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TP33618-TP33618	2.2	
117	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margins. <i>Journal of Clinical Oncology</i> , 2014 , 32, TP33653-TP33653	2.2	
116	Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Blood</i> , 2014 , 124, 3971-3971	2.2	33
115	Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [18F]FDG-PET Prior to Allogeneic Transplant. <i>Blood</i> , 2014 , 124, 1249-1249	2.2	
114	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 447-447	2.2	
113	Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 91-91	2.2	
112	The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 622-622	2.2	
111	Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 316-316	2.2	
110	The genomic landscape of oesophagogastric junctional adenocarcinoma. <i>Journal of Pathology</i> , 2013 , 231, 301-10	9.4	31
109	Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. <i>Journal of the American College of Surgeons</i> , 2013 , 217, 347-57.e1	4.4	35
108	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. <i>European Journal of Cancer</i> , 2013 , 49, 2116-25	7.5	34
107	Neoadjuvant therapy before surgical treatment. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 45-59.6		7
106	Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 15-22	3.8	18
105	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). <i>European Journal of Cancer</i> , 2013 , 49, 3507-16	7.5	18
104	What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. <i>Surgery</i> , 2013 , 154, 1100-9	3.6	11
103	MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 505-11	4	51
102	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 481-9	21.7	533
101	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. <i>Lancet Oncology, The</i> , 2013 , 14, 749-59	21.7	284

100	A RAND/UCLA appropriateness study of the management of familial gastric cancer. <i>Annals of Surgical Oncology</i> , 2013 , 20, 533-41	3.1	11
99	An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. <i>Investigational New Drugs</i> , 2013 , 31, 1228-35	4.3	3
98	Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. <i>Investigational New Drugs</i> , 2013 , 31, 1339-44	4.3	6
97	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. <i>Annals of Oncology</i> , 2013 , 24, 3123-8	10.3	26
96	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. <i>British Journal of Radiology</i> , 2013 , 86, 20130281	3.4	28
95	Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. <i>Pancreas</i> , 2013 , 42, 511-5	2.6	7
94	Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies. <i>Oncologist</i> , 2013 , 18, 833-42	5.7	12
93	Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. <i>European Journal of Cancer Care</i> , 2013 , 22, 714-25	2.4	34
92	Rare case of cerebral MALToma presenting with stroke-like symptoms and seizures. <i>BMJ Case Reports</i> , 2013 , 2013,	0.9	2
91	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14616-e14616	2.2	1
90	HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 420-420	2.2	2
89	COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA4-LBA4	2.2	8
88	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA5-LBA5	2.2	10
87	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 31-31	2.2	
86	Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 78-78	2.2	
85	Preoperative and postoperative chemotherapy for gastric cancer. <i>Surgical Oncology Clinics of North America</i> , 2012 , 21, 99-112	2.7	18
84	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. <i>BMC Cancer</i> , 2012 , 12, 326	4.8	23
83	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , 2012 , 30, 1620-7	2.2	293

82	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2012 , 23, 119-127	10.3	20
81	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2012 , 23, 942-7	10.3	11
80	Primary follicular lymphoma of the GI tract: an increasingly recognized entity. <i>Journal of Clinical Oncology</i> , 2012 , 30, e370-2	2.2	4
79	Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. <i>British Journal of Cancer</i> , 2012 , 106, 1718-21	8.7	28
78	A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA4000-LBA4000	2.2	1
77	A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA4000-LBA4000	2.2	29
76	A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4146-TPS4146	2.2	2
75	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14088-e14088	2.2	
74	Targeting the human EGFR family in esophagogastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 492-503	19.4	120
73	Nonsurgical management of esophageal adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 165-70	3.8	1
72	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. <i>European Journal of Cancer</i> , 2011 , 47, 1146-51	7.5	23
71	Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?. <i>Diseases of the Colon and Rectum</i> , 2011 , 54, 1251-9	3.1	54
70	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. <i>British Journal of Cancer</i> , 2011 , 104, 43-50	8.7	8
69	Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm?. <i>Seminars in Radiation Oncology</i> , 2011 , 21, 196-202	5.5	7
68	Patupilone in cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 107-17	5.9	24
67	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. <i>Annals of Oncology</i> , 2011 , 22, 2042-2048	10.3	167
66	EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3513-3513	2.2	7
65	Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3523-3523	2.2	15

64	REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer. Response rate (RR), toxicity, and molecular analysis from phase II.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4131-4131	2.2	7
63	Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 489-489	2.2	12
62	Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. <i>British Journal of Cancer</i> , 2010 , 102, 255-61	8.7	8
61	The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. <i>Annals of Oncology</i> , 2010 , 21, 1013-9	10.3	38
60	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3945-50	2.2	105
59	Trastuzumab for gastric cancer treatment. <i>Lancet, The</i> , 2010 , 376, 1736; author reply 1736-7	4.0	4
58	Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. <i>Lancet Oncology, The</i> , 2010 , 11, 241-8	21.7	262
57	A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2010 , 28, TPS191-TPS191	2.2	2
56	Chemotherapy for Advanced Pancreatic Cancer 2010 , 913-949		1
55	Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5513-8	2.2	606
54	The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. <i>Annals of Oncology</i> , 2009 , 20, 885-91	10.3	41
53	Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5499-505	2.2	20
52	Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. <i>Journal of Clinical Oncology</i> , 2009 , 27, e3-4	2.2	42
51	Treatment in advanced colorectal cancer: what, when and how?. <i>British Journal of Cancer</i> , 2009 , 100, 1704-19	8.7	81
50	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. <i>British Journal of Cancer</i> , 2009 , 100, 1725-30	8.7	16
49	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. <i>British Journal of Cancer</i> , 2009 , 101, 1033-8	8.7	138
48	Bevacizumab-associated gastrointestinal perforation. <i>Lancet Oncology, The</i> , 2009 , 10, 534-6	21.7	9
47	6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 344-345	1.6	11

46	Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection. <i>Diseases of the Colon and Rectum</i> , 2009 , 52, 669-77	3.1	47
45	Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009 , 4, 54-72	2.6	111
44	Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 456-61	4	105
43	Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. <i>European Radiology</i> , 2008 , 18, 903-10	8	128
42	Capecitabine in gastric cancer. <i>Drugs of Today</i> , 2008 , 44, 629-40	2.5	6
41	Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2007 , 48, 547-50	1.9	15
40	Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. <i>Haematologica</i> , 2007 , 92, 271-2	6.6	86
39	Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). <i>Hematology</i> , 2007 , 12, 149-53	2.2	11
38	Capecitabine in advanced gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2851-61	4	3
37	Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. <i>Annals of Oncology</i> , 2007 , 18, 730-7	10.3	28
36	Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1607-13	4	33
35	Adjuvant therapy in colon cancer--what, when and how?. <i>Annals of Oncology</i> , 2006 , 17, 1347-59	10.3	117
34	Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 668-74	2.2	361
33	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. <i>British Journal of Cancer</i> , 2006 , 94, 1107-15	8.7	63
32	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. <i>Annals of Oncology</i> , 2005 , 16, 549-57	10.3	146
31	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. <i>European Journal of Cancer</i> , 2005 , 41, 1551-9	7.5	18
30	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. <i>British Journal of Cancer</i> , 2005 , 92, 1352-7	8.7	55
29	A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3023-31	2.2	40

28	Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2395-403	2.2	393
27	The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1420-9	2.2	132
26	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. <i>British Journal of Cancer</i> , 2004 , 91, 1453-8	8.7	58
25	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 337-45	59.2	4112
24	The vital role of education and information in patients receiving capecitabine (Xeloda). <i>European Journal of Oncology Nursing</i> , 2004 , 8 Suppl 1, S41-53	2.8	34
23	Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2003 , 88, 1017-24	8.7	68
22	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. <i>British Journal of Cancer</i> , 2003 , 89, 36-42	8.7	56
21	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2003 , 88, 1859-65	8.7	63
20	Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 45, 151-76	7	19
19	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003 , 120, 970-7	4.5	53
18	Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. <i>British Journal of Cancer</i> , 2003 , 88, 1510-5	8.7	15
17	Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. <i>Clinical Colorectal Cancer</i> , 2003 , 3, 19-33	3.8	28
16	Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. <i>Clinical Colorectal Cancer</i> , 2003 , 3, 102-7	3.8	8
15	Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?. <i>New England Journal of Medicine</i> , 2002 , 346, 1085-7	59.2	25
14	Chemotherapy in colorectal cancer: new options and new challenges. <i>British Medical Bulletin</i> , 2002 , 64, 159-80	5.4	23
13	Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3130-6	2.2	104
12	Gemcitabine and its combinations in the treatment of malignant lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002 , 3, 97-104		16
11	Adjuvant therapy in colon cancer: current status and future directions. <i>Cancer Treatment Reviews</i> , 2002 , 28, 223-36	14.4	45

10	An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001 , 115, 786-92	4.5	49
9	Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. <i>British Journal of Cancer</i> , 2001 , 85, 1258-64	8.7	23
8	[18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool. <i>F1000Research</i> , 10 , 1137	3.6	
7	Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer		1
6	Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data		1
5	Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study		2
4	Anus327-332		
3	Colon and Rectum308-326		
2	Anus327-332		
1	Colon and rectum308-326		1